Introduction
============

A solitary fibrous tumour (SFT) is a rare, slow-growing, mesenchymal neoplasm arising from the pleura, which is unrelated to asbestos exposure or cigarette smoking ([@b1-ol-0-0-7798]) and was initially described in 1931 ([@b2-ol-0-0-7798]). Over the past 80 years, SFTs have been identified in numerous extrapleural locations, including the nasal cavity ([@b3-ol-0-0-7798]), breast ([@b4-ol-0-0-7798]), stomach ([@b5-ol-0-0-7798]), bronchus ([@b6-ol-0-0-7798]), head and neck ([@b7-ol-0-0-7798]), liver ([@b8-ol-0-0-7798]), oesophagus ([@b9-ol-0-0-7798]), pelvic ([@b10-ol-0-0-7798]), pancreas ([@b11-ol-0-0-7798]), prostate ([@b12-ol-0-0-7798]), orbit ([@b13-ol-0-0-7798]), central nervous system ([@b14-ol-0-0-7798]), parotid gland ([@b15-ol-0-0-7798]), kidney ([@b16-ol-0-0-7798]), lung ([@b17-ol-0-0-7798]), sella turcica ([@b18-ol-0-0-7798]), heart ([@b19-ol-0-0-7798]), conus medullaris ([@b20-ol-0-0-7798]), omentum ([@b21-ol-0-0-7798]), infratemporal fossa ([@b22-ol-0-0-7798]), bladder ([@b23-ol-0-0-7798]), soft tissues of the extremities ([@b24-ol-0-0-7798]), palatine tonsil ([@b25-ol-0-0-7798]), diaphragm ([@b26-ol-0-0-7798]), mesentery ([@b27-ol-0-0-7798]), lumbar spine ([@b28-ol-0-0-7798]), thymus ([@b29-ol-0-0-7798]), oral cavity ([@b30-ol-0-0-7798]), spermatic cord ([@b31-ol-0-0-7798]), thyroid ([@b32-ol-0-0-7798]), rectum ([@b33-ol-0-0-7798]), salivary glands ([@b34-ol-0-0-7798]), retroperitoneum ([@b35-ol-0-0-7798]), larynx ([@b36-ol-0-0-7798]), trachea ([@b37-ol-0-0-7798]), adrenal gland ([@b38-ol-0-0-7798]), female genital tract ([@b39-ol-0-0-7798]), periosteum of bone ([@b40-ol-0-0-7798]), mediastinum ([@b41-ol-0-0-7798]) and hypopharynx ([@b42-ol-0-0-7798]).

To our knowledge, SFTs are extremely rare in the lung ([@b43-ol-0-0-7798]). There are few detailed case reports concerning the clinical course, imaging characteristics, diagnosis, treatment and prognosis of primary intrapulmonary SFTs. The main purpose of the present study was to report our experience with the diagnosis and management of primary intrapulmonary SFTs and to systematically review previously reported cases in the literature.

Patients and methods
====================

We retrospectively reviewed the records of 5 patients with primary intrapulmonary SFTs who underwent surgical resection at the Department of Cardiothoracic Surgery, Lishui Center Hospital (Lishui, China), and Clinical College of Yangzhou University, (Yangzhou, China), between January 2000 and January 2016. Age, sex, medical history, clinical presentation, diagnostic methods, intraoperative findings, postoperative complications and outcome were retrieved from hospital records. Meanwhile, relevant studies regarding intrapulmonary SFTs were searched via PubMed from January 1990 to January 2016. The text words and MeSH terms 'Solitary fibrous tumours', 'Intrapulmonary', and 'Lung' were used. Tumour characteristics, clinicopathologic features, therapeutic strategy and survival outcomes were reviewed, and these data were tabulated.

Results
=======

### Report of cases

Of the five cases, all were males, with a mean age of 57.6 years (range, 37--68 years). Two patients (nos. 2 and 5) had history of hypertensive disease. One patient (no. 2) had history of diabetes mellitus. One patient (no. 1) had history of bronchial asthma. One patient (no. 3) had history of nodular goitre. The remaining patient (no. 4) had no history of any disease. All patients were asymptomatic, and their tumours were discovered incidentally on routine computed tomography (CT) examination. Contrast-enhanced CT of the chest revealed a lung mass with no calcification or any fatty tissue ([Fig. 1](#f1-ol-0-0-7798){ref-type="fig"}). One, one, one and two tumours occurred in the right lower, left upper, right upper and left lower lung, respectively. Three patients (nos. 1--3) were preoperatively diagnosed with spindle cell tumour by CT-guided percutaneous aspiration biopsy. Other examinations, including pulmonary function, echocardiogram, electrocardiogram, coagulation function and blood routine examination, were normal. The serum levels of Na^+^, K^+^, Cl^−^, Ca^2+^, Mg^2+^ were all within reference range. Serum carbohydrate antigen, carcino-embryonic antigen, squamous cell antigen and neuron-specific enolase were within normal limits. No evidence of metastasis was found via head magnetic resonance imaging (MRI) and abdominal ultrasound.

One patient underwent tumour enucleation though thoracotomy (no. 1), one patient underwent upper left lobectomy associated with lymph node dissection involving radical dissection of the mediastinum (no. 2), and one patient underwent tumour resection associated with bilateral subtotal thyroidectomy (no. 3). The remaining two patients underwent tumour enucleation via video-assisted thoracoscopic surgery (VATS) (nos. 4 and 5) ([Figs. 2](#f2-ol-0-0-7798){ref-type="fig"} and [3](#f3-ol-0-0-7798){ref-type="fig"}). Data of the clinical features are shown in [Table I](#tI-ol-0-0-7798){ref-type="table"}.

The haematoxylin and eosin (H&E) stain showed a rich variety of spindle cells and amorphous areas of collagen ([Fig. 4](#f4-ol-0-0-7798){ref-type="fig"}). Immunohistochemical reactions of the tumour cells were strongly positive for B-cell lymphoma (Bcl)-2 ([Fig. 5](#f5-ol-0-0-7798){ref-type="fig"}) and cluster of differentiation (CD)34 ([Fig. 6](#f6-ol-0-0-7798){ref-type="fig"}). Tumour cells were positive for vimentin (nos. 4 and 5) ([Fig. 7](#f7-ol-0-0-7798){ref-type="fig"}) and CD99 (nos. 2--5) ([Fig. 8](#f8-ol-0-0-7798){ref-type="fig"}). The tumour cells were negative for CD117, desmin, smooth muscle actin (SMA), epithelial membrane antigen and S-100. Following an immunohistochemical-analysis-based study, the diagnosis of intrapulmonary SFTs was made.

Postoperative haemorrhage occurred in one patient (no. 1), and he received surgical intervention for haemostasis. The average time of intrathoracic drain was 3.6 ([@b1-ol-0-0-7798]--[@b9-ol-0-0-7798]) days. The average hospital stay was 15 ([@b4-ol-0-0-7798]--[@b22-ol-0-0-7798]) days, and no mortality occurred. All patients were discharged from the hospital following an uneventfully recovery. The mean length of the postoperative follow-up was 37.6 ([@b1-ol-0-0-7798]--[@b67-ol-0-0-7798]) months. One patient was lost to follow-up, and four patients were asymptomatic.

### Published case study findings

Nineteen articles were identified from the searches of databases ([@b17-ol-0-0-7798],[@b43-ol-0-0-7798]--[@b59-ol-0-0-7798]) ([Table II](#tII-ol-0-0-7798){ref-type="table"}). They had a total of 45 patients: Twenty-three males and 22 females. The mean age was 59.4 years, ranging from 7 to 81 years. Twelve patients were asymptomatic, and pain and cough were the major symptoms. Five, one, two, four, and seventeen tumours occurred in the right upper lobe, right middle lobe, right lower lobe, left upper lobe and left lower lobe, respectively. Thirty-nine patients underwent surgery, one patient underwent radiotherapy, and one patient underwent radiofrequency ablation. Twenty-two patients were followed up, and the mean length of the postoperative follow-up was 48 (1--168) months. One patient was diagnosed with chest wall metastases. Five patients died ([Table III](#tIII-ol-0-0-7798){ref-type="table"}).

### Pathologic and immunohistochemical features

Twenty-eight of 32 cases showed low mitotic counts (0--5/10 HPF), 1 of 32 had a middle mitotic count (0--6/10 HPF), and 3 of 32 showed high mitotic counts (5--10/10 HPF). Immunohistochemical staining analyses were performed in 28 cases. Twenty-four of 28 cases were CD34-positive. Ten of 13 cases were CD99-positive. Fourteen of 15 cases were Bcl-2 positive. Fourteen of 16 cases were vimentin positive. Five of 17 cases were smooth muscle antibody (SMA)-positive. Two of 9 cases were epithelial membrane antigen (EMA) positive. Eight of 9 cases were mib-monoclonal antibody-1 (MIB-1)-positive ([Table IV](#tIV-ol-0-0-7798){ref-type="table"}).

Discussion
==========

SFTs are rare, mesenchymal neoplasms initially described in the pleura but have since been discovered in nearly every anatomic location ([@b61-ol-0-0-7798]). Klemperer and Rabin ([@b62-ol-0-0-7798]) reported 5 cases of primary pleural neoplasms in 1931 and proposed that SFT was of submesothelial origin. However, in the subsequent decades, on the basis of immunohistochemical analyses and ultrastructural features, it is now recognized that SFTs arise from primitive fibroblast-like cells in connective tissue ([@b61-ol-0-0-7798]). SFTs, to our knowledge, most often occur in the pleura. They can be rarely found in the lung, central nervous system, kidney and other extrapleural sites. Via searches of databases, a total of 45 patients with intrapulmonary SFTs were found.

Intrapulmonary SFTs are usually found incidentally and may be associated with chest pain and cough. Seventeen patients (5 in our study and 12 in published literature) were asymptomatic and were discovered incidentally. Two patients presented with pain, and two patients presented with cough. Of note, few patients with SFTs present with refractory hypoglycaemia, which is a paraneoplastic syndrome that secretes a prohormone form of insulin-like growth factor-II (IGF-II), referred to as the Doege-Potter syndrome (DPS).

Due to their atypical clinical and radiographic appearance as a common lung tumour, the diagnosis of intrapulmonary SFTs presents unique challenges. Imaging examinations, including chest X-rays, CT and MRI, are used for assessing intrapulmonary SFTs. There are limited data on X-rays and CT imaging features of intrapulmonary SFTs. The available data show that intrapulmonary SFTs are well-defined ovoid or round pulmonary nodules on chest X-rays and CT scanning, but they are non-specific. The PET-CT findings of SFTs have been rarely reported. PET-CT is a useful tool for evaluating the size, regional invasion and distant metastasis of a tumour. Yan *et al* ([@b63-ol-0-0-7798]) have reported a malignant SFT with mildly increased FDG uptake. Dong *et al* ([@b46-ol-0-0-7798]) have reported a benign SFT with intense FDG uptake. The clinical behaviour of the tumour may be predicted based on PET-CT findings, and FDG uptake degree may be related to the tumour\'s aggressive behaviour ([@b46-ol-0-0-7798]). An intrapulmonary SFT may be identified by CT-guided percutaneous aspiration biopsy. Caruso *et al* ([@b55-ol-0-0-7798]) operated on a pulmonary mass CT-guided FNA cytology biopsy. The FNA cytologic specimen contained spindle cells. Furthermore, FNA cytology, proper clinical and radiologic findings are helpful in narrowing the diagnostic possibilities and making tentative pathologic diagnoses. However, spindle-shaped cells also appear in fibrosarcoma, leiomyosarcoma, schwannoma and others. Therefore, the diagnosis of SFTs may not be identified without immunohistochemical staining. The differential diagnosis of intrapulmonary SFT includes numerous malignant and benign tumours, including pulmonary adenofibroma, benign neural neoplasms, leiomyoma, leiomyosarcoma, synovial sarcoma, spindle cell thymoma, spindle cell carcinoid tumour, nerve sheath tumour, fibrosarcoma, sarcomatoid carcinoma, and sarcomatoid mesothelioma ([@b54-ol-0-0-7798]). To our knowledge, positive CD34, CD99, vimentin and Bcl-2 expression are important markers for the diagnosis of an SFT.

Our review of previously reported cases in the literature suggests complete surgical resection is generally accepted as the definitive and effective treatment of choice for intrapulmonary SFTs. Adequate wedge resection, anatomic segmentectomy and lobectomy, according to the location of mass, are common surgical procedures for resection of intrapulmonary tumours. In our study, three patients underwent adequate wedge resection, whereas the other two patients under anatomic lobectomy. In recent decades, with the development of minimally invasive technology, surgical approaches have been radically changed. More and more intrapulmonary tumours can be safely and availably excised via VATS. In our study, two patients underwent VATS. Previous studies have used radiotherapy and radiofrequency ablation for intrapulmonary SFTs. However, these treatments carry a higher risk of death during follow-up. The effectiveness and capability of such treatment has yet to be confirmed.

Due to their deficiency of information and their languages of publication (not English), some studies were not included in our study. Thirty-six of 681 cases and 8 of 88 cases were SFTs of the lung and pleura, respectively, in Choi\'s *et al* ([@b64-ol-0-0-7798]) and Schirosi\'s *et al* ([@b65-ol-0-0-7798]) studies, and these were not included. Gonullu *et al* ([@b66-ol-0-0-7798]) reported a case of metastatic breast carcinoma to SFT in the lung, and Strickland *et al* ([@b67-ol-0-0-7798]) reported a case of SFT of the uterus presenting with lung metastases. Míguez González *et al* ([@b68-ol-0-0-7798]) reported a case of intrapulmonary SFT associated with haemoptysis, and Masuda *et al* ([@b69-ol-0-0-7798]) report two cases of intrapulmonary tumours with different growth patterns. However, the articles were not written in English. Radulescu *et al* ([@b70-ol-0-0-7798]) reported a case of malignant primary intrapulmonary SFT with haemangiopericytoma-like features.

In conclusion, we retrospectively reviewed the records of 5 patients with primary intrapulmonary SFTs who underwent surgical resection, and we systematically reviewed previously reported cases in the literature. This study has 4 important findings. First, intrapulmonary SFTs can occur in people of all ages and with no sex predominance. The male-to-female ratio was 1.0:0.96. Second, intrapulmonary SFTs are often discovered incidentally. When symptomatic, the common symptoms are chest pain and cough. Third, the left lower lobe was the most common site location. Finally, complete surgical resection is a safe, effective and successful treatment.

![CT scan of the chest demonstrated a 1.5×1.5 cm left lung mass (red arrow). CT, computed tomography.](ol-15-03-3653-g00){#f1-ol-0-0-7798}

![Surgical procedure, partially dissected right upper lung mass.](ol-15-03-3653-g01){#f2-ol-0-0-7798}

![Surgical specimen of 5.5×5×5 cm and weighing 325 g.](ol-15-03-3653-g02){#f3-ol-0-0-7798}

![Haematoxylin and eosin staining showed a rich variety of spindle cells and amorphous areas of collagen (magnification, ×100).](ol-15-03-3653-g03){#f4-ol-0-0-7798}

![The immunohistochemical reactions for Bcl-2 were positive (magnification, ×100). Bcl-2, B-cell lymphoma-2.](ol-15-03-3653-g04){#f5-ol-0-0-7798}

![The immunohistochemical reactions for CD34 protein were positive (magnification, ×100). CD, cluster of differentiation.](ol-15-03-3653-g05){#f6-ol-0-0-7798}

![The immunohistochemical reactions for vimentin protein were positive (magnification, ×100).](ol-15-03-3653-g06){#f7-ol-0-0-7798}

![The immunohistochemical reactions for CD99 protein were positive (magnification, ×100). CD, cluster of differentiation.](ol-15-03-3653-g07){#f8-ol-0-0-7798}

###### 

Patient characteristics and treatment history in our study.

  Features                             Patient no. 1              Patient no. 2                                                Patient no. 3                                    Patient no.4               Patient no.5
  ------------------------------------ -------------------------- ------------------------------------------------------------ ------------------------------------------------ -------------------------- --------------------------
  Sex                                  Male                       Male                                                         Male                                             Male                       Male
  Age (years)                          37                         59                                                           59                                               65                         68
  Presentation                         Asymptomatic               Asymptomatic                                                 Asymptomatic                                     Asymptomatic               Asymptomatic
  Previous history                     Bronchial asthma           hypertensive disease, diabetes mellitus                      Nodular goiter                                   No                         hypertensive disease
  Paraneoplastic syndrome              No                         No                                                           No                                               No                         No
  Location of lesions                  Right lower lobe           left lower lobe                                              Left upper lobe                                  left lower lobe            Right upper lobe
  Surgical strategy                    Thoracotomy                Thoracotomy                                                  Thoracotomy + bilateral subtotal thyroidectomy   VATS                       VATS
  Surgical procedures                  Adequate wedge resection   Left lower lobectomy associated with lymph node dissection   Left upper lobectomy                             Adequate wedge resection   Adequate wedge resection
  Operating time (min)                 100                        120                                                          150                                              75                         35
  Blood loss (ml)                      200                        300                                                          100                                              5                          50
  Size of lesion (cm)                  2.5×3.0                    7×5                                                          6.5×3                                            1.5×1.5                    4×3
  Postoperative complication           Postoperative hemorrhage   no                                                           No                                               No                         no
  Hospital stay (days)                 22                         18                                                           22                                               4                          9
  Time of intrathoracic drain (days)   9                          5                                                            1                                                1                          2
  Cellular pattern                     Spindle                    Spindle                                                      Spindle                                          Spindle                    Spindle
  Mitotic count                        \<1/10HPF                  \>10/10HPF                                                   \<5/10HPF                                        \<1/10HPF                  \<5/10HPF
  CD34                                 \+                         \+                                                           \+                                               \+                         \+
  CD99                                 −                          \+                                                           \+                                               \+                         \+
  Bcl-2                                \+                         \+                                                           \+                                               \+                         \+
  Vimentin                             −                          −                                                            −                                                \+                         \+
  Desmin                               −                          −                                                            −                                                −                          −
  S-100                                −                          −                                                            −                                                −                          −
  SMA                                  −                          −                                                            −                                                −                          −
  Diagnosis                            Benign                     Malignant                                                    Benign                                           Benign                     Benign
  Follow up (months)                   38                         67                                                           55                                               27                         1
  Recurrence                           Unknown                    No                                                           No                                               No                         No
  Present status                       Unknown                    NED                                                          NED                                              NED                        NED

NED, no evidence of disease; VATS, video-assisted thoracoscopic surgery; CD, cluster of differentiation; Blc-2, B-cell lymphoma 2; SMA, smooth muscle actin.

###### 

Clinicopathologic features of intrapulmonary solitary fibrous tumours present in the English literature.

  Authors (ref.)                             Case   Age (years)   Sex      Site                Size           Symptoms                             Treatment                     Follow-up (months)   Status
  ------------------------------------------ ------ ------------- -------- ------------------- -------------- ------------------------------------ ----------------------------- -------------------- ------------
  Cardinal e*t al* ([@b43-ol-0-0-7798])      3      44            Male     Left lower lobe     4 cm           Chest discomfort                     Segmental resection           48                   NED
                                                    64            Male     Left lower lobe     6 cm           asymptomatic                         Left lower lobectomy          36                   NED
                                                    47            Male     Left lower lobe     3 cm           Asymptomatic                         Tumor resection               12                   NED
  Ikeda *et al* ([@b44-ol-0-0-7798])         1      80            Female   Left lower lobe     Unknown        Back pain                            Radiotherapy                  11                   Died
  Sironi *et al* ([@b45-ol-0-0-7798])        1      68            Male     Left lower lobe     8.8×5.7×5 cm   Asymptomatic                         Unknown                       Unknown              Unknown
  Dong *et al* ([@b46-ol-0-0-7798])          1      18            Male     Bilateral lungs     Unknown        asymptomatic                         Unknown                       Unknown              Unknown
  van de Rijn *et al* ([@b47-ol-0-0-7798])   2      69            Male     Unknown             12 cm          Unknown                              Autopsy                       No                   Died
                                                    80            Female   Unknown             Unknown        Unknown                              Unknown                       79                   NED
  Demırağ *et al* ([@b48-ol-0-0-7798])       1      56            Female   Left lung           16 cm          Unknown                              Left pneumonectomy            87                   Unknown
  Barrettara *et al* ([@b49-ol-0-0-7798])    1      81            Female   Left lower lobe     10×9 cm        Left thoracic pain                   Left inferior lobectomy       Unknown              Unknown
  Patsios *et al* ([@b50-ol-0-0-7798])       1      50            Male     Left lower lobe     2.7 cm         Asymptomatic                         Wedge resection               Unknown              Unknown
  Sakurai *et al* ([@b51-ol-0-0-7798])       1      40            Male     Left lower lobe     2.2 cm         Asymptomatic                         Wedge resection               14                   NED
  Sagawa *et al* ([@b52-ol-0-0-7798])        1      72            Female   Left upper lobe     12×9×7 mm      Asymptomatic                         Wedge resection               12                   NED
  Geramizadeh *et al* ([@b53-ol-0-0-7798])   1      7             Male     Right upper lobe    5 cm           Cough and dyspnea                    Right pneumonectomy           9                    NED
  Kawaguchi *et al* ([@b17-ol-0-0-7798])     1      60            Female   Left upper lobe     23×22×19 mm    Asymptomatic                         Left upper segmentectomy      6                    NED
  Rao *et al* ([@b54-ol-0-0-7798])           24     83            Male     Right lung          13.0 cm        Unknown                              Wedge excision or lobectomy   \<60                 NED
                                                    75            Female   Unknown             Unknown                                                                           \<60                 NED
                                                    73            Female   Left lower lobe     2.3 cm                                                                            \<60                 NED
                                                    69            Male     Left lower lobe     Unknown                                                                           \<60                 NED
                                                    59            Female   Unknown             Unknown                                                                           \<60                 NED
                                                    52            Female   Left upper lobe     2.5 cm                                                                            108                  NED
                                                    49            Male     Unknown             18.0 cm                                                                           168                  NED
                                                    58            Female   Left lower lobe     3.9 cm                                                                            \<60                 NED
                                                    46            Male     Right lung          4.5 cm                                                                            156                  NED
                                                    64            Male     Right upper lobe    5.0 cm                                                                            84                   Died
                                                    68            Female   Left lung           Unknown                                                                           Unknown              Unknown
                                                    60            Male     Left lower lobe     Unknown                                                                           Unknown              Unknown
                                                    59            Male     Right upper lobe    Unknown                                                                           Unknown              Unknown
                                                    44            Female   Right upper lobe    Unknown                                                                           Unknown              Unknown
                                                    50            Female   Left lower lobe     Unknown                                                                           Unknown              Unknown
                                                    81            Female   Unknown             7.0 cm                                                                            Unknown              Unknown
                                                    61            Male     Right lower lobe    22.0 cm                                                                           48                   Died
                                                    64            Female   Left lower lobe     12.0 cm                                                                           \<60                 NED
                                                    62            Male     Unknown             8.0 cm                                                                            \<60                 NED
                                                    44            Female   Left lung           4.5 cm                                                                            \<60                 NED
                                                    73            Female   Unknown             3.5 cm                                                                            \<60                 NED
                                                    75            Female   Unknown             10.0 cm                                                                           60                   Chest wall
                                                                                                                                                                                                      metastases
                                                    59            Female   Left lung           10.0 cm                                                                           Unknown              Unknown
                                                    45            Male     Left lower lobe     3.0 cm                                                                            60                   Died
  Caruso *et al* ([@b55-ol-0-0-7798])        1      72            Male     Left lower lobe     6.0 cm         Asymptomatic                         Left lower lobectomy          12                   NED
  Fridlington *et al* ([@b56-ol-0-0-7798])   1      56            Male     Left lower lobe     20 cm          Symptomatic hypoglycemia             Pneumonectomy                 1                    NED
  Kouki *et al* ([@b57-ol-0-0-7798])         1      52            Male     Right upper lobe    5.3×5.0 cm     Asymptomatic                         Right upper lobectomy         24                   NED
  Baliga *et al* ([@b58-ol-0-0-7798])        1      42            Male     Right lower lobe    11 cm          Asymptomatic                         Radiofrequency ablation       No                   Died
  Khalifa *et al* ([@b59-ol-0-0-7798])       1      71            Female   Right middle lobe   2.8 cm         Presistent cough with clear sputum   Wedge lung resection          10                   NED
  Chang *et al* ([@b60-ol-0-0-7798])         1      73            Female   Left lower lobe     3×3×2 cm       Asymptomatic                         Lobectomy                     12                   NED

NED, no evidence of disease.

###### 

Characteristics of the primary intrapulmonary solitary fibrous tumors present in the English literature.

  No. of studies              19
  --------------------------- ------------
  No. cases                   45
  Age (years)                 
    Mean                      59.4
    Range                     7--81
  Tumor sizes (cm)            
    Mean                      8.2
    Range                     2--23
  Sex                         
    Male                      23 (51.1%)
    Female                    22 (48.9%)
  Symptoms                    18
    Asymptomatic              12 (66.7%)
    Pain                      2 (11.1%)
    Cough                     2 (11.1%)
    Other                     2 (11.1%)
  Localization                29
    Right upper lobe          5 (17.2%)
    Right middle lobe         1 (3.5%)
    Right lower lobe          2 (6.9%)
    Left upper lobe           4 (13.8%)
    Left lower lobe           17 (58.6%)
  Treatment                   41
    Surgery                   39 (95.2%)
    Radiotherapy              1 (2.4%)
    Radiofrequency ablation   1 (2.4%)

###### 

Pathologic and immunohistochemical features presented in the English literature.

  Author                                     Mitotic count   Immunohistochemistry
  ------------------------------------------ --------------- ------------------------------------------------------------------------------------------------------------
  Sironi *et al* ([@b45-ol-0-0-7798])        NA              CD34^+^, CD99+
  Dong *et al* ([@b46-ol-0-0-7798])          NA              Vimentin^+^, CD34+, EMA^−^, CAM5.2-, S-100^−^, SMA-, desmin^−^, HMB45-
  van de Rijn *et al* ([@b47-ol-0-0-7798])   NA              CD34^+^, SMA-, MSA^−^, desmin-, AE1^−^, CAM5-
  Demırağ *et al* ([@b48-ol-0-0-7798])       2/10 HPF        CD44^+++^, MMP-2+
  Barrettara *et al* ([@b49-ol-0-0-7798])    2/10 HPF        CD34^+^, CD99+, Bcl-2^+^, vimentin+, calretinin^−^, S100-, actine^−^, CK-
  Patsios *et al* ([@b50-ol-0-0-7798])       NA              Vimentin^+^, CD34: focal+, CK^−^, S-100-, SMA^−^
  Sakurai *et al* ([@b51-ol-0-0-7798])       NA              Vimentin+, CD34^+^, Bcl-2+, CK^−^, desmin-, SMA^−^, S-100-
  Sagawa *et al* ([@b52-ol-0-0-7798])        Rare            CD34^+^, TTF-1-, MIB-1^−^
  Geramizadeh *et al* ([@b53-ol-0-0-7798])   0/10 HPF        Vimentin+, CD34^+^, Bcl-2+, CK^−^, desmin-, SMA^−^, S-100-
  Kawaguchi *et al* ([@b17-ol-0-0-7798])     NA              CD34^+^, calretinin-, SMA^−^, S-100-
  Rao *et al* ([@b54-ol-0-0-7798])           2-5/10 HPF      NA
                                             2-5/10 HPF      Vimentin^+^, p53+, Bcl-2^+^, CD34+, CD99^+^, MIB-1++, CK AE1/AE3^−^, EMA-, S100^−^, SMMS-1-
                                             \<1/10 HPF      NA
                                             \<1/10 HPF      NA
                                             \<1/10 HPF      NA
                                             \<1/10 HPF      NA
                                             2-5/10 HPF      Bcl-2^+^, CD34+, CD99^+^, MIB-1+, SMA^+^, vimentin-, p53^−^, calponin-, AE1/3^−^, EMA-, S100^−^, SMMS1-
                                             \<1/10 HPF      Bcl-2^+^, CD34+, CK AE1/3^−^, SMA-
                                             2-5/10 HPF      NA
                                             \<1/10 HPF      CD34^+^, CD99+, MIB-1^+^, SMA-, CK AE1/3^−^
                                             \<1/10 HPF      NA
                                             2-5/10 HPF      NA
                                             \<1/10 HPF      NA
                                             \<1/10 HPF      NA
                                             \<1/10 HPF      NA
                                             \<1/10 HPF      NA
                                             2-5/10 HPF      Vimentin+++, Bcl-2^+++^, calponin++, CD34^++^, CD99-weak+, CK AE1/3: focal^+^, EMA-, MIB-1^+^, SMA-
                                             \<1/10 HPF      Bcl-2^+++^, CD34+, CD99^+^, MIB-1+, SMA^+^, CK AE1/3-, vimentin^−^, calponin-, EMA^−^,
                                             2-5/10 HPF      Vimentin+++, Bcl-2^+++^, CD34+++, MIB-1^++^, CD99++, calponin^+^, CK AE1/3-, EMA^−^, S100-, SMA^−^, SMMS1-
                                             \<1/10 HPF      CD99^+++^, Bcl-2+++, CD34^+^, p53+, MIB-1^+^, calponin-, AE1/3^−^, EMA-, S100^−^, SMMS1-
                                             \<1/10 HPF      CD99^−^, Bcl-2+++, CD34^++^, p53+, AE1/3^−^, SMA-, vimentin^+++^, SMMS1-
                                             5-10/10 HPF     Bcl-2^+^, CD34+, CD99^+^, SMA+, CK AE1/3^−^
                                             \>10/10 HPF     Vimentin+, Bcl-2^+^, CD99+, p53^−^, calponin-, CD34^−^, CK AE1/3-, S100^−^, SMA-, SMMS1^−^
                                             \>10/10 HPF     MIB-1+++, SMA^++^, EMA+, p53^−^, Bcl-2-, calponin^−^, CD34-, CD99^−^, CK AE1/3-, S100^−^, SMMS1-
  Caruso *et al* ([@b55-ol-0-0-7798])        0-6/10 HPF      Vimentin^+^, keratin-, CEA^−^, EMA+, F VIII^−^, S-100-, desmin^−^, actin-
  Fridlington *et al* ([@b56-ol-0-0-7798])   1-2/10 HPF      CD34^+^, vimentin+, S-100^−^
  Kouki *et al* ([@b57-ol-0-0-7798])         3-4/10 HPF      CD34+
  Baliga *et al* ([@b58-ol-0-0-7798])        0/10 HPF        CD34^++^, Bcl-2+, SMA^+^, CD99-, CAM 5.2^−^, calretinin-
  Khalifa *et al* ([@b59-ol-0-0-7798])       NA              CD34^+^, vimentin+, S-100-, CK^−^, F VIII-, MSA^−^, SMA-
  Chang *et al* ([@b60-ol-0-0-7798])         NA              CD34^+^, vimentin+, S-100^−^, desmin-, CEA^−^, a1-ACT-, F VIII^−^

HPF, high power field; CD, cluster of differentiation; Bcl, B-cell lymphoma; EMA, epithelial membrane antigen; CAM, low molecular weight cytokeratin; CEA, carcinoembryonic antigen; MMP, matrix metalloproteinase; SMMS, smooth muscle myosin; CK, creatine kinase.
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